Specific elimination of anti-DNA antibody-producing cells in systemic lupus erythematosus.

特异性调控抗DNA抗体的产生是系统性红斑狼疮（SLE）治疗的首选方法之一。为此，我们在体外用DNA-D-谷氨酸-D-赖氨酸（DNA-D-GL）诱导了SLE淋巴细胞对DNA的特异性耐受，并使SLE淋巴细胞在体外自发产生的抗ds和/或抗ss DNA抗体明显减少。我们还使用了单克隆抗独特型（Id）抗体与新制癌素（NCS），一种细胞毒性剂的结合。产生抗DNA自身抗体的人B细胞克隆通过用抗Id-NCS缀合物体外处理而被杀死，而表达具有不相关特异性的Id的克隆不受影响。抗Id-NCS还能特异性地抑制人淋巴细胞产生抗DNA自身抗体，这一方法在抑制克隆形成方面具有显著优势，并将为SLE的治疗提供一种有效的方法。

The specific manipulation of anti-DNA antibody production is one of the prefered treatment of systemic lupus erythematosus (SLE). For this purpose, we induced DNE-specific tolerance in vitro using DNA-Dglutamic acid-D-lysine(DNA-D-GL).The addition of the tolerogen reduced markedly the in vitro production of spontaneously occuring anti-ds and/or anti-ss DNA antibodies by SLE lymphocytes. The unresponsiveness was DNA-specific.We also used monoclonal anti-idiotypic (Id) antibodies which were conjugated with neocarzinostatin (NCS), a cytotoxic agent. Human B cell clones, which produce anti-DNA autoantibodies, were killed by by in vitro treatment with anti-Id-NCS conjugates, while clones expressing an Id with irrelevant specificity were unaffected. Anti-Id-NCS also specifically suppressed anti-DNA autoantibodyproductin in vitro by human lymphocytes.This approach will have a significant advantages in aborting clones, and will result in a potent therapeutic treatment for SLE.